Sign in
QNCX Stock Price, Chart, Stats & News
Quince Therapeutics, Inc.
Save
Quince Therapeutics, Inc. (QNCX) does not currently pay a dividend.
7.82M
Market cap
–
Current P/E
–
Forward P/E
QNCX chart
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | -0.13% |
ROA | -51.85% |
ROE | -370.46% |
D/E | 16.99x |
Interest coverage ratio | – |
QNCX valuation
P/E | – |
P/S | – |
P/B | 4.46x |
P/CF | -0.12x |
P/FCF | -0.13x |
P/OCF | -0.12x |
PEG | 0.01x |
EV multiple | 0.12x |
About
Quince Therapeutics, Inc. (QNCX) operates as a biopharmaceutical firm dedicated to developing targeted treatments for debilitating and rare diseases. A cornerstone of their innovation is an extensive bone-targeting drug delivery platform, engineered to accurately transport diverse therapeutic agents, such as small molecules, peptides, and large molecules, directly to affected bone areas like fractures and disease sites. Leading their pipeline is NOV004, an anabolic peptide meticulously designed to pinpoint and accumulate its therapeutic action precisely at bone fracture locations.
Similar securities
Based on sector and market capitalization
Report issue